Connie Wilkinson and Lesley Yeung, Members of the Firm, co-present "Inflation Reduction Act: Win, Lose or Draw for Stakeholders," hosted by the Women Business Leaders of the U.S. Health Care Industry Foundation (WBL).
Prescription drug price reforms have dominated health policy discussions on Capitol Hill and in the Executive Branch for well over a decade. On August 16, 2022, President Biden signed the “Inflation Reduction Act of 2022” (IRA) into law, which includes prescription drug price reform as a focal point.
Connie and Lesley present on changes in store for Medicare stakeholders following the passage of the IRA. They also discuss strategies for managing the impact of the new law.
They share more on:
- Specific provisions in the IRA related to:
- Implementation of the Medicare drug price negotiation program
- Penalties for price increases that outpace inflation
- Redesign of the Medicare Part D benefit
- Replacement of Medicare coverage discount program with a new manufacturer refund program
- Who are the potential winners and losers?
- What to expect when, and how to manage the unknowns
For more information and to register, please visit WBL.org.
